|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
Given the differential binding capacity and the favorable radioactivity pattern, (18) F-RB390 represents the portrayal of the first imaging ligand with predictive potential for mutant T877A-AR in prostate cancer for guiding therapy.Prostate 75:348-359, 2015.© 2014 Wiley Periodicals, Inc.
|
25358634 |
2015 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups.
|
25409505 |
2014 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
It may be particularly effective against prostate cancer cells with the T878A AR mutation but may also enhance degradation of wild-type AR in vivo through a combination of direct and indirect mechanisms.
|
24874833 |
2014 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, we demonstrate that genistein, a soy phytoestrogen binds to both the wild and the Thr877Ala (T877A) mutant types of AR competitively with androgen, nevertheless, it exerts a pleiotropic effect on PCa cell proliferation and AR activity depending on the mutational status of the AR.
|
24167630 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
A total of four human prostate cancer cell models were examined: LNCaP (T877A mutant AR), 22Rv1 (H874Y mutant AR), LAPC4 (wild-type AR), and VCaP (wild-type AR).
|
23813737 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis.
|
21383160 |
2011 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
|
19856921 |
2009 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer.
|
17991730 |
2008 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
Mutation (T877A) of the AR gene found in an androgen-sensitive prostate cancer cell line, LNCaP, has been postulated to be involved in hypersensitivity and loss of specificity for androgen.
|
17312014 |
2007 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A.
|
18007998 |
2007 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
Taken together, these findings provide novel insights into the AR dysfunctions resulting from the T877A mutation and functionally similar AR alterations may provide selective cell growth/survival advantage for CaP progression.
|
16636679 |
2006 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The T877A mutant of the AR frequently found in advanced cases of prostate cancer displays an exaggerated stimulation of transcriptional activity by CDK6.
|
15790678 |
2005 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al.Nature Med.2000, 6, 703-6).
|
11906285 |
2002 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The cortisol/cortisone-responsive AR (AR(ccr)) has two mutations (L701H and T877A) that were found in the MDA PCa human prostate cancer cell lines established from a castrated patient whose metastatic tumor exhibited androgen-independent growth.
|
11956172 |
2002 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
UNIPROT |
|
|
|
|
PROSTATE CANCER, SOMATIC
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Given the differential binding capacity and the favorable radioactivity pattern, (18) F-RB390 represents the portrayal of the first imaging ligand with predictive potential for mutant T877A-AR in prostate cancer for guiding therapy.Prostate 75:348-359, 2015.© 2014 Wiley Periodicals, Inc.
|
25358634 |
2015 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
It may be particularly effective against prostate cancer cells with the T878A AR mutation but may also enhance degradation of wild-type AR in vivo through a combination of direct and indirect mechanisms.
|
24874833 |
2014 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups.
|
25409505 |
2014 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we demonstrate that genistein, a soy phytoestrogen binds to both the wild and the Thr877Ala (T877A) mutant types of AR competitively with androgen, nevertheless, it exerts a pleiotropic effect on PCa cell proliferation and AR activity depending on the mutational status of the AR.
|
24167630 |
2013 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of four human prostate cancer cell models were examined: LNCaP (T877A mutant AR), 22Rv1 (H874Y mutant AR), LAPC4 (wild-type AR), and VCaP (wild-type AR).
|
23813737 |
2013 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis.
|
21383160 |
2011 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
|
19856921 |
2009 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The androgen-mediated repression of hTERT is abrogated in a human prostate cancer cell line exhibiting hormone-dependent growth, which expresses a mutant AR (T877A) frequently occurring in prostate cancer.
|
17991730 |
2008 |
|
Prostate carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A.
|
18007998 |
2007 |